# South America Point of Care Molecular Diagnostics Market

> South America Point-of-care Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Applications (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology), and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.82%
- **2024:** $ 312.39 Million
- **2025:** $ 333.69 Million
- **2035:** $ 645.4 Million
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Cepheid (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Qiagen N.V. (NL), BD (Becton, Dickinson and Company) (US), GenMark Diagnostics (US)

**Report ID:** MRFR/MED/49961-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-point-of-care-molecular-diagnostics-market-51719

---

## Market Summary

## **South America****Point-of-care****Molecular Diagnostics Market Overview**

As per MRFR analysis, the South America Point-of-care Molecular Diagnostics Market Size was estimated at 288.5 (USD Million) in 2023.The South America Point-of-care Molecular Diagnostics Market is expected to grow from 312.5(USD Million) in 2024 to 750 (USD Million) by 2035. The South America Point-of-care Molecular Diagnostics Market CAGR (growth rate) is expected to be around 8.284% during the forecast period (2025 - 2035).

**Key South America****Point-of-care****Molecular Diagnostics Market Trends Highlighted**

The growing need for quick and accurate diagnostic solutions is propelling the South American point-of-care molecular diagnostics market's notable expansion. The increasing incidence of infectious diseases, such as bacterial, viral, and parasite infections, has increased the demand for prompt diagnostics in clinical settings, making it one of the major market drivers.

Additionally, because molecular diagnostics may provide precise information about a person's health condition, their adoption is being fuelled by the increased emphasis on personalised medicine and the demand for customised treatment alternatives. This region offers a wealth of prospects, especially in underdeveloped communities where healthcare infrastructure is still in its infancy.

Point-of-care diagnostics can now be delivered to rural populations through a unique channel because to the growth of telemedicine and improvements in mobile health technologies. Furthermore, more funding for molecular diagnostics may result from regional healthcare strategies targeted at enhancing disease management and control, which would improve access to cutting-edge medical treatments.

Recent trends also show a move towards integrated diagnostics systems, which incorporate several testing modalities into one instrument to provide quicker results and more efficient workflow. Additionally, as more South American countries back programs to help domestic biotech enterprises, there is an increasing focus on local production and innovation.

This lessens reliance on foreign sources and is consistent with national initiatives to increase healthcare resilience. All things considered, the South American point-of-care molecular diagnostics market presents a vibrant landscape with changing demands, technological breakthroughs, and a strong emphasis on accessibility and regional solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America****Point-of-care****Molecular Diagnostics Market Drivers**

**Rising Demand for Rapid Diagnostic Solutions**

The South America Point-of-care Molecular Diagnostics Market is experiencing significant growth due to the increasing demand for rapid diagnostic solutions. The COVID-19 pandemic highlighted the need for swift testing and immediate results to contain the spread of the virus.

According to the Pan American Health Organization (PAHO), the surge in infectious diseases has prompted many South American countries to invest in innovative diagnostic technologies.

For instance, Brazil's Ministry of Health has implemented policies to increase access to rapid diagnostic tests, with a target of increasing testing capacity by 20% in 2024. This shift towards faster diagnostics is expected to drive the growth of the market significantly.

**Technological Advancements in Molecular Diagnostics**

Technological advancements in the molecular diagnostics field are a major driver for the South America Point-of-care Molecular Diagnostics Market. Innovations in polymerase chain reaction (PCR) and next-generation sequencing technologies have enhanced diagnostic accuracy and speed.

As per the Brazilian Society of Clinical Pathology, there has been an increase of over 15% in the adoption of molecular diagnostic technologies over the past three years. Major companies like Roche and Abbott are expanding their portfolios to include advanced Point-of-care testing kits tailored for local markets, further propelling growth and improving healthcare outcomes.

**Increasing Incidence of Infectious Diseases**

The rising incidence of infectious diseases in South America is an essential factor driving the growth of the Point-of-care Molecular Diagnostics Market. The World Health Organization (WHO) reported a 30% increase in reported cases of infectious diseases such as influenza and tuberculosis in South America in the last five years.

These alarming statistics have pushed governments, like Argentina's Ministry of Health, to prioritize investments in Point-of-care diagnostics. By 2025, it is projected that hospitals will allocate an additional 10% of their budgets towards rapid diagnostic systems, ultimately advancing the market landscape.

**South America****Point-of-care****Molecular Diagnostics Market Segment Insights**

**Point-of-care****Molecular Diagnostics Market Product Type Insights**

The South America Point-of-care Molecular Diagnostics Market presents a diverse landscape under the Product Type segment, encompassing various testing methodologies that are poised to enhance diagnostic capabilities in the region.

Among these, PCR Tests stand out as a widely utilized method due to their ability to deliver rapid results with high sensitivity and specificity, making them crucial in infectious disease control, including outbreaks and public health emergencies.

Nucleic Acid Amplification Tests have gained traction as they allow for the detection of pathogens and genetic disorders, significantly contributing to personalized medicine initiatives and timely treatment decisions, hence fostering patient-centric care.

Microarray technology, although not as dominant as PCR and Nucleic Acid Amplification Tests, plays a valuable role in comprehensive profiling and diagnostics through its multi-target detection capabilities, which is particularly beneficial in epidemiological studies and in understanding complex disease mechanisms.

Next-Generation Sequencing offers transformative insights into genetics by enabling thorough genomic analysis, thus facilitating advancements in understanding rare diseases and cancer genomics. Lastly, Other Genetic Tests, which encompass a variety of methodologies focused on discovering genetic abnormalities and mutations, are critical for targeted therapies and improving health outcomes.

The integration of these diverse methodologies responds to the increasing demand for accurate and rapid diagnostic solutions in South America, driven by the rising prevalence of infectious diseases and genetic disorders.

Furthermore, the regional emphasis on improving healthcare infrastructure and investing in technology enhances the overall accessibility and utility of Point-of-care Molecular Diagnostics, ensuring that these advanced testing methods are integral to the future of healthcare in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Point-of-care****Molecular Diagnostics Market Application Insights**

The South America Point-of-care Molecular Diagnostics Market is segmented into various applications, which play a critical role in enhancing healthcare delivery. Among these applications, infectious diseases diagnostics hold considerable significance due to the high prevalence of diseases like COVID-19 and other epidemics in the region, necessitating rapid and accurate testing solutions.

Genetic testing emerges as a vital tool, offering insights into hereditary conditions and aiding personalized medicine approaches that are gaining traction in South America. Furthermore, cancer diagnosis is increasingly important as cancer incidence rates rise, driving demand for early detection and monitoring methods in various countries across the continent.

Metabolic disorders also represent a significant application area, particularly addressing the growing concerns surrounding diabetes and obesity, which pose public health challenges.

Overall, the diverse applications within the South America Point-of-care Molecular Diagnostics Market collectively contribute to improving patient outcomes and reducing the burden on healthcare systems, reflecting an ongoing trend toward more accessible and efficient healthcare solutions.

**Point-of-care****Molecular Diagnostics Market****End-use****Insights**

The End-use segment of the South America Point-of-care Molecular Diagnostics Market showcases a diverse landscape influenced by the need for efficient and timely diagnostics. Hospitals play a crucial role, leveraging Point-of-care diagnostics to enhance patient management and expedite decision-making processes, thereby driving better health outcomes.

Diagnostic laboratories are increasingly adopting advanced molecular diagnostic techniques, ensuring accurate results which contribute to the rise in public health initiatives across the region. Home care settings are gaining traction, reflecting the growing trend towards patient autonomy and convenience, particularly in rural areas where access is limited.

Outpatient clinics, being at the forefront of healthcare delivery, are integrating Point-of-care solutions to streamline patient flow and improve service efficiency. Together, these segments are reshaping the healthcare framework in South America, addressing increasing demands for rapid testing solutions and facilitating broader access to essential healthcare services.

The regulatory landscape and supportive government initiatives are further bolstering the market growth, making this segment an essential focal point in enhancing health care delivery across the continent.

**Point-of-care****Molecular Diagnostics Market Technology Insights**

The Technology segment of the South America Point-of-care Molecular Diagnostics Market reflects a growing landscape driven by innovation and the need for rapid diagnostic solutions. Isothermal Amplification technology has gained momentum due to its simplicity and efficiency, enabling timely results without the need for complex equipment.

Polymerase Chain Reaction continues to dominate as a cornerstone technique, known for its sensitivity and reliability in detecting genetic material. Sanger Sequencing offers comprehensive insights into genetic variations, making it valuable in personalized medicine and research applications.

Meanwhile, CRISPR Technology is emerging as a groundbreaking tool in diagnostics, providing unprecedented precision in gene editing and disease detection.

Each of these technologies contributes significantly to addressing public health challenges and disease monitoring in South America, fostering advancements in healthcare accessibility and quality. As the region's focus on improving health outcomes intensifies, these technologies are expected to play critical roles in shaping the future of diagnostics and pushing the boundaries of molecular biology.

**Point-of-care****Molecular Diagnostics Market Regional Insights**

The South America Point-of-care Molecular Diagnostics Market has shown significant growth, driven by the increasing demand for rapid and accurate diagnostic tools across the region. Brazil is a leader in this market, demonstrating a strong focus on improving healthcare infrastructure and access to Point-of-care molecular diagnostics, supported by ongoing investments in health technology.

Mexico also plays a crucial role, showing a rising prevalence of chronic diseases that necessitate effective diagnostic solutions, while Argentina contributes with a growing emphasis on disease prevention and monitoring.

In the Rest of South America, various countries are recognizing the importance of Point-of-care molecular diagnostics as a means to enhance health outcomes, leading to greater governmental and private sector initiatives to expand these services.

The trends in the South America Point-of-care Molecular Diagnostics Market highlight a shift towards more personalized and timely medical care, aligning with global health trends and addressing the unique healthcare challenges faced by the region.

As demand for these innovative solutions rises, opportunities for collaborations between local and international providers continue to emerge, paving the way for enhanced market dynamics in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America****Point-of-care****Molecular Diagnostics Market Key Players and Competitive Insights**

The South America Point-of-care Molecular Diagnostics Market has witnessed significant growth driven by advancements in technology, an increasing prevalence of infectious diseases, and a rising demand for rapid diagnostic solutions. The competitive landscape in this market is characterized by a mix of established global players and emerging local companies.

The market is evolving with innovations in point-of-care testing, which aim to provide quicker results and improve patient outcomes in various healthcare settings. With the growing emphasis on personalized medicine and decentralized healthcare, companies are actively developing and marketing products tailored to meet the unique needs of the South American population.

This dynamic environment creates both opportunities and challenges for participants, necessitating continuous adaptation and strategic positioning to maintain a competitive edge.

Roche Holding AG emerges as one of the key players in the South America Point-of-care Molecular Diagnostics Market, leveraging its strong brand recognition and a comprehensive portfolio of diagnostic solutions. The company has established a robust market presence through strategic partnerships and a deep understanding of regional healthcare challenges.

Roche's capabilities in innovative molecular diagnostics technologies, combined with extensive research and development efforts, enhance its competitive position. The company’s strengths lie in its ability to deliver reliable and timely diagnostic results, which are critical in improving patient management in both hospital and outpatient settings.

Roche’s commitment to high-quality products and its active engagement in local healthcare initiatives further solidify its standing in the region.

PerkinElmer Inc holds a significant foothold in the South America Point-of-care Molecular Diagnostics Market, focusing on delivering advanced technologies and solutions that address the specific needs of the local healthcare environment.

The company's product offerings include a diverse range of diagnostic tools that enhance disease detection and management, particularly in infectious diseases and genetic testing. PerkinElmer's strengths include innovative product development, a strong distribution network, and a reputation for high-quality diagnostics, which have contributed to its market growth in this region.

Additionally, the company has pursued strategic partnerships and collaborations to expand its reach and bolster its capabilities. Recent mergers and acquisitions have allowed PerkinElmer to enhance its product portfolio and strengthen its market presence, positioning itself as a leader in delivering point-of-care solutions tailored to the diverse healthcare requirements in South America.

**Key Companies in the South America****Point-of-care****Molecular Diagnostics Market Include:**

- Roche Holding AG
- PerkinElmer Inc
- Luminex Corporation
- Trinity Biotech
- BD (Becton, Dickinson and Company)
- Qiagen N.V.
- Abbott Laboratories
- Thermo Fisher Scientific Inc
- Cepheid
- Siemens Healthineers
- GenMark Diagnostics
- LumiraDx
- BioRad Laboratories
- Hologic Inc

**South America****Point-of-care****Molecular Diagnostics****Market****Developments**

Recent developments in the South America Point-of-care Molecular Diagnostics Market include significant advancements in technology and product offerings by key players like Roche Holding AG, Abbott Laboratories, and BD (Becton, Dickinson and Company).

The market has been witnessing increasing adoption of rapid testing solutions, particularly in response to public health needs driven by the COVID-19 pandemic, which surged demand for accessible diagnostic tools.

There have been no notable mergers or acquisitions reported within this sector recently, highlighting a focus on organic growth and innovation among companies such as Thermo Fisher Scientific Inc and Siemens Healthineers.

Additionally, the growth of the market is supported by increased healthcare investments and government initiatives aimed at enhancing diagnostic capabilities across Brazil, Argentina, and Colombia, as part of a broader strategy to improve public health infrastructure.

Over the past two to three years, key events include the launch of innovative diagnostic platforms tailored to local healthcare needs, underscoring a dynamic shift towards precision medicine and rapid testing in this region, with an emphasis on affordability and accessibility for diverse populations.

**South America****Point-of-care****Molecular Diagnostics Market Segmentation Insights**

**Point-of-care Molecular Diagnostics Market Product Type Outlook**

- PCR Tests
- Nucleic Acid Amplification Tests
- Microarray
- Next-Generation Sequencing
- Other Genetic Tests

**Point-of-care Molecular Diagnostics Market Application Outlook**

- Infectious Diseases
- Genetic Testing
- Cancer Diagnosis
- Metabolic Disorders

**Point-of-care Molecular Diagnostics Market End-useOutlook**

- Hospitals
- Diagnostic Laboratories
- Home Care Settings
- Outpatient Clinics

**Point-of-care Molecular Diagnostics Market Technology Outlook**

- Isothermal Amplification
- Polymerase Chain Reaction
- Sanger Sequencing
- CRISPR Technology

**Point-of-care Molecular Diagnostics Market Regional Outlook**

- Brazil
- Mexico
- Argentina
- Rest of South America

## Market Drivers

### Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases in South America is a crucial driver for the point of-care-molecular-diagnostics market. With diseases such as dengue fever, Zika virus, and tuberculosis becoming more prevalent, there is a heightened need for rapid and accurate diagnostic tools. The World Health Organization indicates that the region has seen a surge in these diseases, necessitating immediate testing solutions. This demand is further amplified by the need for timely interventions to control outbreaks. The point of-care-molecular-diagnostics market is thus positioned to grow as healthcare providers seek efficient diagnostic methods to address these public health challenges. The market is projected to expand significantly, with estimates suggesting a growth rate of approximately 15% annually over the next few years.

### Growing Awareness of Personalized Medicine

The shift towards personalized medicine in South America is influencing the point of-care-molecular-diagnostics market. As healthcare providers increasingly focus on tailored treatment plans based on individual patient profiles, the demand for precise diagnostic tools rises. Molecular diagnostics play a pivotal role in identifying specific biomarkers, which are essential for personalized treatment strategies. The point of-care-molecular-diagnostics market is thus experiencing growth as clinicians seek to implement these advanced diagnostic methods. The market is expected to witness a compound annual growth rate (CAGR) of around 12% as healthcare systems adapt to this evolving paradigm. This trend underscores the importance of molecular diagnostics in enhancing patient outcomes.

### Rising Demand for Home Healthcare Solutions

The growing trend of home healthcare solutions in South America is impacting the point of-care-molecular-diagnostics market. As patients increasingly prefer receiving care in the comfort of their homes, there is a rising demand for portable and user-friendly diagnostic devices. This shift is prompting manufacturers to develop innovative point-of-care testing solutions that can be used outside traditional clinical settings. The point of-care-molecular-diagnostics market is thus poised for growth, as these solutions offer convenience and accessibility to patients. Market analysts predict a growth rate of around 14% in this segment, reflecting the changing dynamics of healthcare delivery in the region.

### Technological Integration in Healthcare Systems

The integration of advanced technologies into healthcare systems in South America is a significant driver for the point of-care-molecular-diagnostics market. Innovations such as artificial intelligence and machine learning are being utilized to enhance diagnostic accuracy and efficiency. These technologies facilitate the rapid analysis of molecular data, enabling healthcare providers to make informed decisions swiftly. The point of-care-molecular-diagnostics market is likely to benefit from this technological evolution, as healthcare facilities adopt these tools to improve patient care. The market is projected to grow by approximately 18% over the next five years, driven by the increasing adoption of technology in diagnostics.

### Increased Investment in Healthcare Infrastructure

Investment in healthcare infrastructure across South America is driving the point of-care-molecular-diagnostics market. Governments and private entities are recognizing the importance of enhancing healthcare facilities, particularly in remote and underserved areas. This investment is aimed at improving access to diagnostic services, which is essential for effective disease management. The point of-care-molecular-diagnostics market benefits from this trend as new facilities are equipped with advanced diagnostic technologies. Furthermore, the allocation of funds towards healthcare is expected to increase, with projections indicating a rise of 20% in healthcare spending by 2027. This financial commitment is likely to facilitate the adoption of molecular diagnostics, thereby expanding the market.

## Future Outlook

The [Point of Care Molecular Diagnostics Market](https://www.marketresearchfuture.com/reports/point-of-care-molecular-diagnostics-market-11484) is projected to grow at 6.82% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for rapid testing, and rising healthcare investments.

**New opportunities:**

- Development of portable diagnostic devices for remote areas
- Integration of AI for enhanced diagnostic accuracy
- Expansion of telehealth services incorporating molecular diagnostics

By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility.

## Segment Insights

### By Type: PCR Tests (Largest) vs. Next-Generation Sequencing (Fastest-Growing)

The market for point-of-care molecular diagnostics in South America is currently dominated by PCR Tests, which hold the largest share among the various segment values. Following PCR Tests, Nucleic Acid Amplification Tests also contribute significantly, while Microarray and Other Genetic Tests occupy smaller portions of the market. Next-Generation Sequencing is emerging, showing promising growth and gaining traction among healthcare providers as a reliable diagnostic tool. Growth trends within this segment are being driven by an increasing demand for rapid and accurate diagnostic solutions, especially in response to recent public health challenges. Innovations in technology are leading to enhanced sensitivity and specificity of tests, bringing about an uptick in adoption rates. The focus on personalized medicine is further propelling interest in advanced testing methodologies, including Next-Generation Sequencing, which is now seen as a key player in the evolving landscape of diagnostics.

PCR Tests (Dominant) vs. Next-Generation Sequencing (Emerging)

PCR Tests have established themselves as the dominant segment in the point-of-care molecular diagnostics realm, primarily due to their proven reliability and rapid results, making them essential for various diseases. This method is widely recognized for its ability to offer timely diagnostic information, which is crucial in clinical settings. On the other hand, Next-Generation Sequencing, although currently categorized as emerging, is rapidly gaining ground thanks to its capability to analyze multiple genes simultaneously and provide comprehensive insights into genetic disorders. This technology appeals to researchers and clinicians alike for its potential in advancing personalized treatment, thereby positioning itself as a significant player in the future of molecular diagnostics.

### By Application: Infectious Diseases (Largest) vs. Genetic Testing (Fastest-Growing)

In the market for point-of-care molecular diagnostics, the distribution among application segments highlights Infectious Diseases as the dominant player, significantly capturing market share due to ongoing health crises and a rise in pathogenic outbreaks. This segment's prominence is further strengthened by technological advancements that facilitate rapid diagnosis and treatment initiation, essential in curbing disease transmission. Conversely, [Genetic Testing](https://www.marketresearchfuture.com/reports/genetic-testing-market-2009) is emerging as the fastest-growing segment, spurred by increasing public awareness and advancements in genomics. The integration of molecular diagnostics in personalized medicine and preventive healthcare is driving growth in this sector. Rising demand for early and accurate diagnosis for hereditary conditions and the accessibility of testing services contribute to its rapid expansion, signaling strong future potential in the market.

Infectious Diseases (Dominant) vs. Genetic Testing (Emerging)

Infectious Diseases stand out as the dominant application segment in point-of-care molecular diagnostics, primarily driven by high rates of infections and the need for immediate diagnostic capabilities in emergency settings. This segment benefits from established protocols and technology that streamline diagnosis for diseases like influenza, HIV, and COVID-19. On the other hand, Genetic Testing is heralded as the emerging segment, reflecting a growing trend towards personalized medicine. With advancements in genomic technologies and decreasing costs of testing, this segment is gaining traction, particularly for conditions that require early intervention. The collaboration between healthcare providers and genetic testing companies enhances the service delivery framework, making genetic testing more accessible and effective.

### By End Use: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the South America point of-care-molecular-diagnostics market, hospitals dominate the end-use segment due to their extensive infrastructure and acute patient care capabilities. They are pivotal in deploying advanced molecular diagnostic technologies, which enhances patient outcomes and operational efficiencies. Meanwhile, diagnostic laboratories are also a strong contributor, utilizing cutting-edge diagnostic kits to cater to diverse tests and patient needs. Home care settings have emerged as the fastest-growing segment, fueled by the increasing preference for at-home testing and monitoring solutions. This trend is driven by factors such as convenience, cost-effectiveness, and rapid advancements in portable diagnostic technologies. Outpatient clinics are also notable, providing accessible diagnostic services to patients without the need for hospital admission, thereby supporting the expansion of point-of-care diagnostics in the region.

Hospitals: Dominant vs. Home Care Settings: Emerging

Hospitals play a dominant role in the point-of-care molecular diagnostics market due to their advanced medical technologies and comprehensive healthcare services. They are well-equipped with resources that enable them to implement sophisticated diagnostic tests, thus ensuring timely and accurate patient care. On the other hand, home care settings represent an emerging trend, appealing to patients seeking more personalized and flexible health management solutions. The shift towards home diagnostics is supported by technological innovations in molecular testing, which allow patients to perform tests conveniently in their own environments. As both segments develop, they cater to the varying needs of the South American population, reflecting a transformation in healthcare delivery.

### By Technology: Polymerase Chain Reaction (Largest) vs. CRISPR Technology (Fastest-Growing)

In the South America point of-care-molecular-diagnostics market, Polymerase Chain Reaction (PCR) stands as the largest segment, capturing a significant share due to its efficiency and reliability in nucleic acid amplification. Isothermal Amplification and Sanger Sequencing also play vital roles, but they currently hold smaller market shares compared to PCR. CRISPR Technology, on the other hand, is emerging quickly and is poised to reshape diagnostics with its novel applications and precision. Growth trends in this segment are driven by advancements in technology and increasing demand for rapid, accurate diagnostic tools. The rise in infectious diseases and the need for timely results further accelerate the adoption of technologies like PCR and CRISPR. The flexibility and cost-effectiveness of Isothermal Amplification make it a noteworthy contender, while Sanger Sequencing continues to maintain relevance in specialized applications. These dynamics illustrate a competitive landscape rich in innovation and opportunity.

Technology: PCR (Dominant) vs. CRISPR (Emerging)

Polymerase Chain Reaction (PCR) remains the dominant technology in the South America point of-care-molecular-diagnostics market, known for its robustness and established effectiveness in amplifying DNA and RNA. It is widely used due to its reliability and broad applicability across various infectious diseases. In contrast, CRISPR Technology is viewed as an emerging powerhouse due to its groundbreaking potential in gene editing and real-time diagnostics. CRISPR's rapidly evolving capabilities promise not only enhanced accuracy but also reduced turnaround times. As research and development continue, CRISPR is likely to capture a larger share of the market, reflecting trends toward innovation and personalized medicine.

## Regional Market Share Analysis

### Brazil : Robust Growth and Innovation Hub

Brazil holds a dominant position in the South American point-of-care molecular diagnostics market, with a market value of $135.0 million, accounting for a significant share. Key growth drivers include increasing healthcare investments, rising prevalence of infectious diseases, and government initiatives aimed at enhancing healthcare access. Regulatory policies are becoming more favorable, promoting innovation and adoption of advanced diagnostic technologies. Infrastructure improvements, particularly in urban areas, are facilitating better healthcare delivery and diagnostics access.

### Mexico : Growing Demand and Investment Opportunities

Mexico's point-of-care molecular diagnostics market is valued at $75.0 million, reflecting a growing demand driven by rising healthcare awareness and increasing incidences of chronic diseases. Government initiatives to enhance healthcare access and affordability are also contributing to market growth. The regulatory environment is evolving, with efforts to streamline approval processes for new diagnostic technologies, fostering innovation in the sector.

### Argentina : Focus on Accessibility and Quality

Argentina's market for point-of-care molecular diagnostics is valued at $50.0 million, supported by a growing emphasis on healthcare quality and accessibility. Key growth drivers include increasing public health initiatives and a rising demand for rapid diagnostic solutions. The government is actively promoting policies to enhance healthcare infrastructure, which is crucial for the adoption of advanced diagnostic technologies in rural and urban areas alike.

### Rest of South America : Regional Growth and Collaboration

The Rest of South America, with a market value of $52.39 million, presents diverse opportunities in the point-of-care molecular diagnostics sector. Growth is driven by increasing healthcare investments and regional collaborations aimed at improving diagnostic capabilities. Regulatory frameworks are being strengthened to support innovation, while local governments are focusing on enhancing healthcare access across various sectors, including infectious disease management and chronic care.

## Competitive Benchmarking

The point-of-care molecular diagnostics market in South America is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for rapid diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Cepheid (US) are strategically positioned to leverage innovation and regional expansion. Abbott Laboratories (US) focuses on enhancing its product portfolio through continuous innovation, while Roche Diagnostics (CH) emphasizes partnerships to strengthen its market presence. Cepheid (US) appears to be concentrating on expanding its manufacturing capabilities to meet the growing demand for point-of-care testing, collectively shaping a competitive environment that is increasingly reliant on technological prowess and strategic collaborations.
The market structure is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of South America’s diverse regulatory landscape. The collective influence of these major players fosters a competitive atmosphere where innovation and operational efficiency are paramount, allowing them to respond swiftly to market demands and regulatory changes.
In October 2025, Roche Diagnostics (CH) announced a strategic partnership with a local biotechnology firm to enhance its point-of-care testing capabilities in Brazil. This collaboration is expected to facilitate the development of tailored diagnostic solutions that cater to regional health challenges, thereby solidifying Roche's foothold in the South American market. The strategic importance of this partnership lies in its potential to accelerate product development cycles and improve access to advanced diagnostics in underserved areas.
In September 2025, Abbott Laboratories (US) launched a new rapid molecular diagnostic test specifically designed for respiratory infections, targeting the South American market. This launch is significant as it not only expands Abbott's product offerings but also addresses the urgent need for timely diagnostics in a region where respiratory diseases are prevalent. The introduction of this test may enhance Abbott's competitive edge by providing healthcare providers with rapid and accurate diagnostic tools.
In August 2025, Cepheid (US) expanded its manufacturing facility in Colombia to increase production capacity for its GeneXpert systems. This expansion is crucial as it allows Cepheid to meet the rising demand for point-of-care molecular diagnostics in the region. By enhancing its production capabilities, Cepheid is likely to improve its supply chain reliability and responsiveness to market needs, positioning itself favorably against competitors.
As of November 2025, current trends in the point-of-care molecular diagnostics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver rapid, accurate diagnostics tailored to local needs.

## Recent News & Developments

Recent developments in the South America Point-of-care Molecular Diagnostics Market include significant advancements in technology and product offerings by key players like Roche Holding AG, Abbott Laboratories, and BD (Becton, Dickinson and Company).

The market has been witnessing increasing adoption of rapid testing solutions, particularly in response to public health needs driven by the COVID-19 pandemic, which surged demand for accessible diagnostic tools.

There have been no notable mergers or acquisitions reported within this sector recently, highlighting a focus on organic growth and innovation among companies such as Thermo Fisher Scientific Inc and Siemens Healthineers.

Additionally, the growth of the market is supported by increased healthcare investments and government initiatives aimed at enhancing diagnostic capabilities across Brazil, Argentina, and Colombia, as part of a broader strategy to improve public health infrastructure.

Over the past two to three years, key events include the launch of innovative diagnostic platforms tailored to local healthcare needs, underscoring a dynamic shift towards precision medicine and rapid testing in this region, with an emphasis on affordability and accessibility for diverse populations.

**South America Point-of-care**

## Report Scope

| MARKET SIZE 2024 | 312.39(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 333.69(USD Million) |
| MARKET SIZE 2035 | 645.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Cepheid (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Qiagen N.V. (NL), BD (Becton, Dickinson and Company) (US), GenMark Diagnostics (US) |
| Segments Covered | Type, Application, End Use, Technology |
| Key Market Opportunities | Emerging technologies enhance rapid testing capabilities in the point of-care-molecular-diagnostics market. |
| Key Market Dynamics | Rising demand for rapid testing drives innovation in point-of-care molecular diagnostics across South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the current valuation of the South America point-of-care molecular diagnostics market?**
A: The market valuation was $312.39 Million in 2024.

**Q: What is the projected market size for the South America point-of-care molecular diagnostics market by 2035?**
A: The projected valuation for 2035 is $645.4 Million.

**Q: What is the expected CAGR for the South America point-of-care molecular diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.82% during the forecast period.

**Q: Which companies are the key players in the South America point-of-care molecular diagnostics market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Cepheid, Thermo Fisher Scientific, Hologic, Inc., Qiagen N.V., BD, and GenMark Diagnostics.

**Q: What are the main types of tests contributing to the market, and what were their valuations in 2024?**
A: In 2024, PCR Tests were valued at $160.0 Million, Nucleic Acid Amplification Tests at $140.0 Million, Microarray at $100.0 Million, Next-Generation Sequencing at $120.0 Million, and Other Genetic Tests at $125.4 Million.

**Q: What applications are driving the South America point-of-care molecular diagnostics market?**
A: In 2024, Infectious Diseases accounted for $200.0 Million, Genetic Testing for $150.0 Million, Cancer Diagnosis for $120.0 Million, and Metabolic Disorders for $75.4 Million.

**Q: What end-use segments are prominent in the South America point-of-care molecular diagnostics market?**
A: In 2024, Hospitals generated $210.0 Million, Diagnostic Laboratories $160.0 Million, Home Care Settings $100.0 Million, and Outpatient Clinics $175.4 Million.

**Q: What technologies are utilized in the South America point-of-care molecular diagnostics market, and what were their valuations in 2024?**
A: In 2024, Polymerase Chain Reaction was valued at $250.0 Million, Isothermal Amplification at $100.0 Million, Sanger Sequencing at $150.0 Million, and CRISPR Technology at $145.4 Million.

**Q: How does the market growth in South America compare to other regions?**
A: While specific comparisons are not provided, the projected growth rate of 6.82% during 2025 - 2035 suggests a robust expansion in the South America market.

**Q: What factors are likely to influence the growth of the South America point-of-care molecular diagnostics market?**
A: Factors may include advancements in technology, increasing demand for rapid diagnostics, and the growing prevalence of infectious diseases and genetic disorders.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-point-of-care-molecular-diagnostics-market-51719*